Company begins Phase I clinical trials on drug to treat dry eye, allergic conjunctivitis.
The San Francisco Business Times (9/5) reported that "SARcode Corp. has started a Phase I clinical trial of a drug aimed at" treating dry eye and allergic conjunctivitis, "and will pay a $500,000 to its partner Sunesis Pharmaceuticals Inc. as a result." SARcode will pay an additional "milestone if the treatment makes it into a Phase II trial." The Business Times noted that "SARcode is a small, private company with five employees overseeing contract researchers" that focuses primarily "on work on inflammatory disease treatments."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment